DDInter1705 DDInter1676
Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Sparfloxacin {u} (Compound) resembles {v} (Compound) Lomefloxacin
Sparfloxacin {u} (Compound) binds {v} (Gene) SLC22A5
Sparfloxacin {u} (Compound) upregulates {v} (Gene) KCTD5
Sparfloxacin {u} (Compound) downregulates {v} (Gene) PKIG
Sparfloxacin {u} (Compound) causes {v} (Side Effect) Atrial flutter
Sparfloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Temozolomide
Sparfloxacin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Paclitaxel
Sparfloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Zinc sulfate
Sparfloxacin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ibuprofen
Sparfloxacin {u} may lead to a major life threatening interaction when taken with {v} Vandetanib
Sparfloxacin (Compound) resembles Lomefloxacin (Compound)
Sparfloxacin (Compound) binds SLC22A5 (Gene)
Sparfloxacin (Compound) upregulates KCTD5 (Gene)
Sparfloxacin (Compound) downregulates PKIG (Gene)
Sparfloxacin (Compound) causes Atrial flutter (Side Effect)
Sparfloxacin may cause a minor interaction that can limit clinical effects when taken with Temozolomide
Sparfloxacin may cause a minor interaction that can limit clinical effects when taken with Paclitaxel
Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Zinc sulfate
Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen
Sparfloxacin may lead to a major life threatening interaction when taken with Vandetanib